A Migration and Bone Density Study Comparing 2 Types of Bone Cement in the OptiPac Bone Cement Mixing System
Information source: University of Aarhus
Information obtained from ClinicalTrials.gov on October 19, 2009 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Osteoarthritis
Intervention: Refobacin Bone Cement R (Other); Refobacin Plus Bone Cement (Other)
Phase: N/A
Status: Recruiting
Sponsored by: University of Aarhus Official(s) and/or principal investigator(s): Kjeld Soballe, MD, Prof., Principal Investigator, Affiliation: Orthopaedic Center, Aarhus University Hospital, Tage-Hansens Gade 2, 8000 Ã…rhus C, Denmark
Overall contact: Maiken Stilling, MD, Phone: 0045 89497466, Email: mm-p@dadlnet.dk
Summary
The goal of this scientific study is to determine whether there are differences in early
migration and prosthesis-near bone density when a standard knee prosthesis is fixed with
Refobacin Bone Cement R or with Refobacin Plus Bone Cement. Migration will be evaluated with
RSA and bone density around the prosthesis with DEXA. The study will be successful if the
prosthesis is fixed and remains in place throughout the entire period of the study, that is,
that there is no increasing migration as measured by RSA. The cement type that ensures the
largest number of solidly fixed prostheses during the two-year evaluation period will be
"the best".
Clinical Details
Official title: A Migration and Bone Density Study Comparing Refobacin Bone Cement R vs. Refobacin Plus Bone Cement in the OptiPac Bone Cement Mixing System. A Prospective Randomized Study on Primary Total Knee Arthroplasty
Study design: Diagnostic, Randomized, Single Blind (Subject), Active Control, Parallel Assignment, Safety/Efficacy Study
Primary outcome: Tibial implant migration evaluated by RSA
Secondary outcome: Comparison of Refobacin Bone Cement R vs. Refobacin Plus Bone Cement
Detailed description:
Loosening of prosthetic components continues to play a large role in total knee alloplasty
(TKA) and need for revision. Osteolysis is an important part of prosthesis loosening, but we
still do not completely understand the mechanism. Research has shown that mechanical factors
such as weak bone cement and poor contact between cement/bone or cement/implant interphase
contribute to loosening of implants. Survival of cemented TKA components also depend on a
careful balancing of soft tissues around the knee, repair of lower extremity dislocations,
design of the prosthesis and the level of patients' activities. Sclerosis of the proximal
tibia can present a problem with regard to getting the cement to penetrate into the bone.
Poor operative technique, such as high volume or high pressure lavage of the prepared bone
surface, can result in reduced penetration of cement into the spongiosa and early failure of
the prosthesis, measured as progressive radiolucent lines (RLLs). En tourniquet counter acts
bleeding at the implant site and provides for better penetration of cement into the
trabeculae of the bone. If the bone surface at the implantation site is contaminated with
blood before the cement is applied, the shear strength in the bone/cement interphase can be
reduced by up to 50%.
In prosthesis used in this study includes a tibial plateau with a central stem with
stabilizing wings, the bottom surface of which is recessed by about 1 mm, so that a pocket
is formed surrounded by a lip that provides for an even thickness of the cement layer
beneath the tibial plateau. This assures that the cement is pressed down into the spongiosa
during fixation of the implant. This design doubles the penetration of the cement compared
with prostheses without a depressed baseplate. The company behind this design has had a
successful follow-up of this system for more than 15 years. A good cement/implant interphase
lessens the risk of penetration of debris into the interphase and thus reduces the risk for
the development of osteolysis and aseptic loosening of the implant.
Fixation of knee alloplasties is done in 70% of cases with use of cement. It is uncertain
whether there is a difference in the long-term survival of knee prostheses with the two
types of cement used in this project. Both types of cement in this study are used today in
knee surgery with good, short-term clinical results. It is important to investigate new
types of cement in order to assure future patients the best possible results after knee
alloplasty and fewer re-operations.
The goal of this scientific study is to determine whether there are differences in early
migration and prosthesis-near bone density when a standard knee prosthesis is fixed with
Refobacin Bone Cement R or with Refobacin Plus Bone Cement. Migration will be evaluated with
RSA and bone density around the prosthesis with DEXA. The study will be successful if the
prosthesis is fixed and remains in place throughout the entire period of the study, that is,
that there is no increasing migration as measured by RSA. The cement type that ensures the
largest number of solidly fixed prostheses during the two-year evaluation period will be
"the best".
Eligibility
Minimum age: 70 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- primary or secondary knee osteoarthritis
- sufficient bone quality for total knee arthroplasty
- age above 70 years
- no upper age limit if the patient is capable
- informed and written consent
- patient can only enter the project with one knee
Exclusion Criteria:
- neuromuscular or vascular disease in the affected leg
- preoperatively not found suitable for a knee arthroplasty
- patients with osteoporosis based on former diagnosis or preoperative DEXA-scan
- fracture sequelae or previous PTO or previous extensive knee surgery
- patients with need of a stem-elongation
- patients who cannot refrain from taking NSAID post-operatively
- continuous medical treatment with vitamin K antagonists (Warfarin) which is known to
reduce the bon emineral density by a factor of 5
- patients with metabolic bone disease
- patients with rheumatoid arthritis
- postmenopausal women in estrogenic hormone substitution
- patients with a continuous need of systemic cortisone treatment
- non-Danish citizenship
- patients who do not comprehend the Danish language (read and speak)
- senile dementia
- alcoholism - defined as men drinking more than 21 units a week and women drinking
more than 14 units a week
- drug abuse
- major psychiatric disease
- metastatic cancer disease and treatment with radiation therapy or chemotherapy
- severe systemic disease (e. g. hemi paresis and Parkinson disease)
- systemic hip and spine disease
- employee at the orthopaedic department, Aarhus University Hospital
- ongoing case regarding industrial injury insurance of the knee
- patients with poor dental status (risk of infection)
Locations and Contacts
Maiken Stilling, MD, Phone: 0045 89497466, Email: mm-p@dadlnet.dk
Orthopaedic Center, Aarhus University Hospital, Aarhus 8000, Denmark; Recruiting Maiken Stilling, MD, Phone: 0045 89497466, Email: mm-p@dadlnet.dk Kjeld Soballe, MD, Prof., Phone: 0045 89497425, Email: kjeld.soeballe@as.aaa.dk Maiken Stilling, MD, Sub-Investigator Frank Madsen, MD, Sub-Investigator Anders Odgaard, MD, DMSc, Sub-Investigator Kjeld Soballe, MD, Prof., Principal Investigator
Additional Information
Starting date: June 2008
Ending date: September 2012
Last updated: September 16, 2009
|